First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors

Criteria for Selection of Patient Population Inclusion Criteria

- Patients with advanced solid tumor that is refractory to standard treatment, for which
no standard treatment is available, or the patient refuses standard therapy.

- ≥ 18 years old at the time of informed consent.

- ECOG Performance Status 0 or 1.

- Patients must have adequate hematologic and organ function.

- Patients must be willing and able to sign the informed consent form, and to follow the
study visit schedule and other protocol requirements.

- Women of childbearing potential and men must agree to use effective contraceptive
methods while on study and for at least twelve weeks after the last dose of study
drug.

- Women of childbearing potential must have a negative pregnancy test prior to the first
dose of study treatment.

Exclusion Criteria

- Grade >1 neuropathy

- Any active or chronic corneal disorder and Sjogren's syndrome.

- Serious concurrent illness:

- Any other concomitant anti-cancer treatment.

- Women of childbearing potential who are pregnant or breast feeding.